Islet transplantation became one of the most promising Type 1 diabetes treatment in clinical practice. However, the immuno suppressant usage after the surgery became the bottleneck of the islet survival factor. Seeking the new replacement of suppressant is currently the hot research focus.
Arsenic trioxide is known as an effective drug in the treatment of acute myeloid leukemia and has recently been shown to inhibit allograft rejection. This study focused on the inhibitory effect of arsenic trioxide on the immunological rejection of islet allografts,and further investigated the possible mechanism of the combination application of arsenic trioxide and rapamycin on the immune tolerance after allograft. The research team demonstrates that Arsenic trioxide is anti-inflammatory, and is able to influence cytokine synthesis and secretion, as well as shifting T cell subsets population. Thus, arsenic trioxide suppressed allogeneic immune response in protecting islet graft from allograft rejection was via weaken T lymphocyte functions. This study was published on Transplantation.
（1st October 2015）